A New Transatlantic Bridge for Medical Technology Innovation

MORGAN HILL, CA – July 07, 2026 – In a move that speaks volumes about the future of global healthcare, U.S.-based manufacturing specialist PDV MedTech and German engineering powerhouse Corscience have announced a strategic partnership designed to create a seamless, end-to-end pathway for medical device innovators. This transatlantic alliance isn't just another corporate handshake; it's a structural solution to a problem that has long plagued the industry: the fragmented, costly, and time-consuming journey of bringing a life-saving device from a European lab to a U.S. hospital, or vice versa.

The medical technology landscape is growing at a staggering pace, with the contract development and manufacturing (CDMO) market projected to surpass $270 billion by 2033. Yet, this growth is fraught with complexity. Devices are becoming smarter and more interconnected, while regulatory frameworks, like the European Union’s stringent Medical Device Regulation (EU MDR), have become formidable barriers to entry. This partnership aims to build a bridge over these troubled waters, combining German engineering rigor with American manufacturing scale.

A Blueprint for Global Development

The alliance marries two distinct but highly complementary skill sets. Corscience, based in Germany's medtech hub of Erlangen, has spent 25 years mastering the development of safety-critical devices—the complex Class IIb and III products like defibrillators and advanced patient monitors where, as CEO Dr. Jörg Pintaske notes, “failure is not an option.” Their core strength lies in deep domain knowledge of hardware and software engineering, coupled with invaluable hands-on experience navigating the EU MDR approval process.

On the other side of the Atlantic, PDV MedTech, an INDO-MIM company, brings a formidable manufacturing and development infrastructure to the table. With roots going back over two decades and experience on more than 600 projects, the company offers a scalable production path from its R&D-focused facilities in California and Utah to high-volume manufacturing in Texas and globally through its parent company’s network in India, Mexico, and the U.K. This infrastructure provides the engine for commercialization that many European innovators lack direct access to.

“For 25 years, PDV MedTech has been focused on helping innovative solutions reach the market and make a meaningful impact on patients,” said Bryant Grigsby, CEO of PDV MedTech. “The partnership gives medtech innovators a more complete path from early-stage development to manufacturing.”

The model is designed for flexibility. A U.S. startup can leverage PDV MedTech's local prototyping capabilities while simultaneously engaging Corscience to ensure its design is compliant with European standards from day one. Conversely, a German company can perfect its device with Corscience and then seamlessly transition to PDV MedTech’s FDA-registered facilities to scale production for the lucrative U.S. market. It addresses the perennial challenge of 'design for manufacturability' by ensuring the engineers who design the device are in lockstep with the people who will build it at scale.

Navigating the Regulatory Maze

For many medtech companies, navigating the differing regulatory demands of the U.S. Food and Drug Administration (FDA) and the EU MDR is one of the single greatest hurdles to global commercialization. The frameworks require different approaches to clinical evidence, technical documentation, and post-market surveillance. This partnership creates a unified regulatory strategy, effectively offering a 'two-for-one' compliance pathway.

By integrating Corscience’s EU MDR expertise at the project's outset, companies can avoid the costly redesigns and documentation overhauls that often occur when a device developed for one market is retrofitted for another. This is particularly crucial for the high-risk devices both companies specialize in. An implantable cardiac device or a connected patient monitoring system must be built on a foundation of regulatory compliance, not have it bolted on as an afterthought.

The alliance provides a single, trusted source for innovators who lack the internal bandwidth or specialized knowledge to manage this dual-track process. This de-risks the journey for startups and mid-sized firms, which are often the source of breakthrough innovations but are also most vulnerable to the financial shocks of regulatory delays or rejections.

A Strategic Play in a Consolidating Market

This partnership does not exist in a vacuum. It is a savvy strategic maneuver in a highly competitive global market. As industry giants like Jabil and Flex expand their end-to-end services, this alliance represents a different approach: a collaboration of specialists. Rather than one massive entity trying to be everything to everyone, this is a targeted partnership that combines best-in-class expertise from two distinct domains.

For PDV MedTech’s parent company, INDO-MIM, a global leader in precision component manufacturing, this move signals a deliberate and aggressive push up the value chain. The 2025 acquisition of Phoenix DeVentures (now PDV MedTech) was the first step in moving beyond components into full-service device development. The Corscience alliance is the next logical evolution, adding a critical European R&D and regulatory competency that transforms INDO-MIM’s medtech division into a truly global, concept-to-commercialization powerhouse.

By uniting their strengths, PDV MedTech and Corscience are creating a new model for public trust in the digital age of medicine. They are building an infrastructure designed not just for efficiency, but for resilience and compliance. This integrated approach ensures that as medical devices become more complex and integral to our lives, the systems that create them are robust enough to earn the confidence of patients and clinicians worldwide.